These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Savickiene J; Borutinskaite VV; Treigyte G; Magnusson KE; Navakauskiene R Eur J Pharmacol; 2006 Nov; 549(1-3):9-18. PubMed ID: 16978604 [TBL] [Abstract][Full Text] [Related]
7. The molecular mechanism of HDAC inhibitors in anticancer effects. Bi G; Jiang G Cell Mol Immunol; 2006 Aug; 3(4):285-90. PubMed ID: 16978537 [TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors: overview and perspectives. Dokmanovic M; Clarke C; Marks PA Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399 [TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. Moldenhauer A; Frank RC; Pinilla-Ibarz J; Holland G; Boccuni P; Scheinberg DA; Salama A; Seeger K; Moore MA; Nimer SD J Leukoc Biol; 2004 Sep; 76(3):623-33. PubMed ID: 15197237 [TBL] [Abstract][Full Text] [Related]
10. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. Jones P; Altamura S; De Francesco R; Paz OG; Kinzel O; Mesiti G; Monteagudo E; Pescatore G; Rowley M; Verdirame M; Steinkühler C J Med Chem; 2008 Apr; 51(8):2350-3. PubMed ID: 18370373 [TBL] [Abstract][Full Text] [Related]
11. Development of histone deacetylase inhibitors for cancer treatment. Marchion D; Münster P Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177 [TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797 [TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors in cancer therapy. Fouladi M Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962 [No Abstract] [Full Text] [Related]
14. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297 [TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors: biology and mechanism of action. Mehnert JM; Kelly WK Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243 [TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor. Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008 [TBL] [Abstract][Full Text] [Related]
17. Differentiation of eosinophilic leukemia EoL-1 cells into eosinophils induced by histone deacetylase inhibitors. Ishihara K; Takahashi A; Kaneko M; Sugeno H; Hirasawa N; Hong J; Zee O; Ohuchi K Life Sci; 2007 Mar; 80(13):1213-20. PubMed ID: 17258775 [TBL] [Abstract][Full Text] [Related]
18. Role of histone deacetylase inhibitors in the treatment of cancer (Review). Mei S; Ho AD; Mahlknecht U Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685 [TBL] [Abstract][Full Text] [Related]
19. Optimization of a series of potent and selective ketone histone deacetylase inhibitors. Pescatore G; Kinzel O; Attenni B; Cecchetti O; Fiore F; Fonsi M; Rowley M; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P Bioorg Med Chem Lett; 2008 Oct; 18(20):5528-32. PubMed ID: 18809328 [TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Piekarz RL; Sackett DL; Bates SE Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]